Molecular mechanism of acquired drug resistance in the EGFR-TKI resistant cell line HCC827-TR.

ABSTRACT:

Background

The first-line standard treatment of non-small cell lung cancer (NSCLC) with EGFR mutation is EGFR-tyrosine kinase inhibitors (TKIs). However, most patients will develop acquired resistance after 9-13 months. This study investigated novel molecular mechanisms of acquired resistance to EGFR-TKIs to identify a potential new treatment for EGFR-TKI resistant NSCLC patients.

Methods

We established an EGFR-TKI resistant cell line (HCC827-TR) by culturing the HCC827-P cell line through continuous erlotinib culture. We used Sanger sequencing, RT-PCR, and western blot to rule out known resistance mechanisms in HCC827-TR cells, including EGFR-T790M and MET, PTEN, or EGFR expression changes. Next-generation sequencing was performed and identified differentially expressed gen

SUBMITTER: Yu T 

PROVIDER: S-EPMC7180561 | biostudies-literature | 2020 May

REPOSITORIES: biostudies-literature